- Home
- CDIO vs MYNZ Comparison
CDIO vs MYNZ Comparison
Compare CDIO & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDIO | MYNZ |
|---|---|---|
| Founded | 2017 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CDIO | MYNZ |
|---|---|---|
| Price | $2.88 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 31.0K | ★ 928.5K |
| Earning Date | 11-12-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $15,782.00 | ★ $659,935.00 |
| Revenue This Year | $1,434.82 | N/A |
| Revenue Next Year | $4,661.91 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.42 | $0.92 |
| 52 Week High | $53.10 | $8.20 |
Technical Indicators
Market Signals| Indicator | CDIO | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 39.14 | 43.04 |
| Support Level | $2.84 | $1.00 |
| Resistance Level | $3.22 | $1.13 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 31.12 | 20.51 |
Price Performance
Historical ComparisonAbout CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.